जर्नल ऑफ़ बोन रिसर्च
खुला एक्सेस

अमूर्त

Ponatinib before and after Allogeneic Stem Cell Transplantation for Ph+ Acute Lymphoblastic Leukemia or Lymphoid Blast Crisis of Chronic Myelogenous Leukemia: A Single Center Experience

Federica Sora, Patrizia Chiusolo, Luca Laurenti, Simona Soverini and Simona Sica

Role of Ponatinib, given as bridge to transplantation or at relapse after aSCT in patients affected by Philadelphia acute lymphoblastic leukemia (ALL) or lymphoid BC-CML is also not well understood. We report a retrospective analysis that included allograft recipients with blast phase chronic myeloid leukemia or (Ph+) acute lymphoblastic leukemia who had received ponatinib before and/or after aSCT. Patients were all assessed for BCR/ABL mutations before ponatinib administration and after relapse: only two patients showed compound mutation. At a median of 21 months 6 out of 7 patients have died from disease progression and one patient died from septic shock after aSCT. In our experience ponatinib, given as bridge to transplantation or at relapse after aSCT, is useful to obtain a rapid hematological response in almost all patients and occasionally morphological and molecular response, but unfortunately they were short-lived.